Antibodies to SARS-CoV-2 and risk of future sickness
Open Access
- 18 September 2020
- preprint content
- other
- Published by Cold Spring Harbor Laboratory
Abstract
Background The extent that antibodies to SARS-CoV-2 may protect against future virus-associated disease is unknown. Method We analyzed 12928 healthy hospital employees for SARS-CoV-2 antibodies and compared results to participant sick leave records (Clinical trial registration: https:ClinicalTrials.gov NCT04411576). Results Subjects with viral serum antibodies were not at excess risk for future sick leave (Odds Ratio (OR): 0.85 (95% Confidence Interval (CI) (0.85 (0.43-1.68)). By contrast, subjects with antibodies had an excess risk for sick leave in the past weeks (OR: 3.34 (2.98-3.74)). Conclusion Presence of viral antibodies marks past disease and protection against excess risk of future disease.Keywords
This publication has 8 references indexed in Scilit:
- Profile of RT-PCR for SARS-CoV-2: A Preliminary Study From 56 COVID-19 PatientsClinical Infectious Diseases, 2020
- Prevalence of Asymptomatic SARS-CoV-2 InfectionAnnals of Internal Medicine, 2020
- Antibody responses to SARS-CoV-2 in patients with COVID-19Nature Medicine, 2020
- Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing FacilityThe New England Journal of Medicine, 2020
- Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19The New England Journal of Medicine, 2020
- Defining the Epidemiology of Covid-19-Studies NeededThe New England Journal of Medicine, 2020
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformationScience, 2020
- Individual and stable autoantibody repertoires in healthy individualsAutoimmunity, 2019